Short Interest in ADMA Biologics Inc (NASDAQ:ADMA) Expands By 35.0%

ADMA Biologics Inc (NASDAQ:ADMA) was the recipient of a significant growth in short interest in March. As of March 13th, there was short interest totaling 25,826,838 shares, a growth of 35.0% from the February 26th total of 19,137,458 shares. Approximately 11.3% of the company’s stock are sold short. Based on an average daily volume of 3,625,752 shares, the short-interest ratio is currently 7.1 days.

ADMA Biologics Price Performance

Shares of ADMA opened at $9.25 on Monday. The company has a 50-day simple moving average of $15.60 and a 200-day simple moving average of $16.42. The firm has a market capitalization of $2.20 billion, a P/E ratio of 15.42 and a beta of 0.51. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71. ADMA Biologics has a 52 week low of $7.21 and a 52 week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business had revenue of $139.16 million for the quarter, compared to the consensus estimate of $139.80 million. During the same period last year, the business earned $0.46 earnings per share. The firm’s revenue for the quarter was up 18.4% compared to the same quarter last year. On average, equities research analysts expect that ADMA Biologics will post 0.51 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the sale, the chief operating officer owned 466,600 shares of the company’s stock, valued at $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steve Elms purchased 7,000 shares of the firm’s stock in a transaction dated Thursday, March 5th. The shares were bought at an average price of $15.67 per share, with a total value of $109,690.00. Following the purchase, the director owned 2,038,730 shares in the company, valued at $31,946,899.10. This represents a 0.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 3.70% of the company’s stock.

Institutional Trading of ADMA Biologics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Summit Securities Group LLC bought a new stake in shares of ADMA Biologics in the 4th quarter worth about $29,000. Salomon & Ludwin LLC bought a new position in ADMA Biologics during the 3rd quarter valued at about $25,000. Rothschild Investment LLC lifted its holdings in ADMA Biologics by 373.8% during the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,495 shares during the last quarter. Optima Capital LLC acquired a new position in ADMA Biologics in the fourth quarter valued at about $36,000. Finally, Clearstead Advisors LLC boosted its position in ADMA Biologics by 55.7% in the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 795 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Wall Street Zen upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Zacks Research raised ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $32.00.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Company issues formal refutation of Culper Research’s allegations, calling the report “unsubstantiated, misleading and inaccurate” and defending ASCENIV’s competitive position and revenue recognition. ADMA refutes short-seller claims
• Positive Sentiment: Market coverage notes a rebound after the company’s rebuttal — headlines and articles report ADMA “gains” as traders react to management’s statements. ADMA gains after refuting claims
• Positive Sentiment: Analysts and media flag market attention including Nasdaq reactions and commentary that the company is actively addressing investor concerns — helpful for short‑term sentiment. Market attention coverage
• Neutral Sentiment: Unusual options activity was reported (large call buying), suggesting speculative positioning that can amplify intraday moves but not fundamental direction. (Options volume reported in market notices.)
• Neutral Sentiment: Context pieces note ADMA is down significantly since its last earnings release, highlighting volatility tied to recent results and expectations — useful for evaluating risk vs. reward. Zacks: stock down since earnings
• Negative Sentiment: Multiple securities‑fraud investigations and investor alerts have been launched by a number of law firms after the short report and the subsequent price decline — this increases legal risk and could pressure the stock. Investor investigations announced
• Negative Sentiment: Short‑seller allegations (including claims of channel stuffing) remain in circulation via reports and investor alerts; third‑party scrutiny prompted steep intraday declines last week and remains a key downside risk. Investor alert on short‑seller report
• Negative Sentiment: Cantor Fitzgerald moved the stock after the short‑report fallout (coverage/ratings action reported), adding analyst pressure on sentiment. Cantor Fitzgerald downgrade

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.